{"disease":{"id":"vascularization","name":"vascularization"},"drugs":{"marketed":[{"drug_id":"ranibizumab-eqrn","indication_name":"Myopic Choroidal Neovascularization (mCNV)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"CIMERLI","generic_name":"RANIBIZUMAB-EQRN","company_name":"SANDOZ INC","drug_phase":"marketed","molecular_target":"","drug_class":"Vascular Endothelial Growth Factor Inhibitor [EPC]","quality_score":18,"revenue":null,"mechanism":""},{"drug_id":"fluvastatin-sodium","indication_name":"Reduce Risk of Coronary Revascularization","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"FLUVASTATIN SODIUM","company_name":"","drug_phase":"marketed","molecular_target":"HMG-CoA reductase","drug_class":"","quality_score":60,"revenue":null,"mechanism":"Fluvastatin inhibits HMG-CoA reductase, reducing cholesterol synthesis."},{"drug_id":"verteporfin","indication_name":"Choroidal retinal neovascularization","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Visudyne","generic_name":"VERTEPORFIN","company_name":"Bausch Lomb Ireland","drug_phase":"marketed","molecular_target":"","drug_class":"Photoenhancer [EPC]","quality_score":10,"revenue":null,"mechanism":"Visudyne selectively binds to neovascular tissue, which is then activated by light to induce a phototoxic reaction."},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device and a Solitaire FR Revascularization Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device and a Solitaire FR Revascularization Device and a Stentriever Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Solitaire FR Revascularization Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device and a Solitaire FR Revascularization Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Solitaire FR Revascularization Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device and a Solitaire FR Revascularization Device and a Stentriever Device and a Trevo Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device and a Solitaire FR Revascularization Device and a Trevo Device and a Penumbra System","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Solitaire FR Revascularization Device and a Trevo Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Solitaire FR Revascularization Device and a Penumbra System","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device and a Solitaire FR Revascularization Device and a Stentriever Device and a Trevo Device and a Penumbra System","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device and a Solitaire FR Revascularization Device and a Stentriever Device and a Penumbra System","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device and a Solitaire FR Revascularization Device and a Trevo Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"visudyne","indication_name":"Choroidal retinal neovascularization","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Visudyne","company_name":"Bayer","drug_phase":"discontinued","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"lucentis","indication_name":"Choroidal retinal neovascularization","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Lucentis","company_name":"Santen Inc.","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke (Mechanical Thrombectomy) - Solitaire FR Revascularization Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"ranibizumab-nuna","indication_name":"Choroidal retinal neovascularization","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BYOOVIZ","generic_name":"RANIBIZUMAB-NUNA","company_name":"SAMSUNG BIOEPIS CO LTD","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"","quality_score":null,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":19,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07130968","title":"Real-World Cohort Study of Cardiopulmonary Function in Chinese Patients With Cardiovascular Disease: CPET Evaluation and Five-Year Prognostic Follow-Up Based on a Multicenter Structured Data Platform","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":200000,"lead_sponsor_name":"Guangdong Provincial People's Hospital","has_results":false},{"nct_id":"NCT04691037","title":"CCTA Improves Clinical Management of Stable Chest Pain","phase":"","overall_status":"RECRUITING","enrollment_count":50000,"lead_sponsor_name":"Tianjin Chest Hospital","has_results":false},{"nct_id":"NCT02425345","title":"Women's Health Initiative Strong and Healthy Study","phase":"NA","overall_status":"COMPLETED","enrollment_count":49331,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":true},{"nct_id":"NCT03776266","title":"The Long-term Clinical Outcomes and Patterns of Transfusion in PCI Patients: Retrospective Cohort Study","phase":"","overall_status":"COMPLETED","enrollment_count":48786,"lead_sponsor_name":"Samsung Medical Center","has_results":false},{"nct_id":"NCT03788148","title":"Bare Metal Stents and Drug Eluting Stents in Patients Who Underwent Blood Transfusion","phase":"","overall_status":"COMPLETED","enrollment_count":28322,"lead_sponsor_name":"Samsung Medical Center","has_results":false},{"nct_id":"NCT06766084","title":"Is Total Arterial Revascularization Superior to Multiarterial Grafting in Coronary Artery Bypass Grafting","phase":"","overall_status":"COMPLETED","enrollment_count":7878,"lead_sponsor_name":"Technion, Israel Institute of Technology","has_results":false},{"nct_id":"NCT05284747","title":"EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction","phase":"PHASE4","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":6019,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT05416853","title":"Radial Versus Femoral Access For Carotid Artery Stenting","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":3000,"lead_sponsor_name":"The First Affiliated Hospital of University of Science and Technology of China","has_results":false},{"nct_id":"NCT04837001","title":"Evaluation in STEMI Patients Using FDY-5301","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":2351,"lead_sponsor_name":"Faraday Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT03256513","title":"The Safety and Efficacy of Peri-procedure Blood Pressure Management of Revascularization","phase":"NA","overall_status":"UNKNOWN","enrollment_count":2270,"lead_sponsor_name":"Xuanwu Hospital, Beijing","has_results":false},{"nct_id":"NCT00001733","title":"Screening for Studies on Retinovascular Diseases","phase":"","overall_status":"COMPLETED","enrollment_count":2000,"lead_sponsor_name":"National Eye Institute (NEI)","has_results":false},{"nct_id":"NCT02307682","title":"Efficacy and Safety of RTH258 Versus Aflibercept - Study 1","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1775,"lead_sponsor_name":"Alcon Research","has_results":true},{"nct_id":"NCT03229941","title":"Transfusion Trigger After Operations in High Cardiac Risk Patients","phase":"NA","overall_status":"COMPLETED","enrollment_count":1424,"lead_sponsor_name":"VA Office of Research and Development","has_results":true},{"nct_id":"NCT02434328","title":"Efficacy and Safety of RTH258 Versus Aflibercept - Study 2","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1048,"lead_sponsor_name":"Alcon Research","has_results":true},{"nct_id":"NCT05532631","title":"Percutaneous Coronary RevascularizatiOn VERsus Coronary-Artery Bypass Grafting for Multivessel Disease in Patients With Left Ventricular Dysfunction (PROVERB)","phase":"NA","overall_status":"RECRUITING","enrollment_count":1040,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT03491722","title":"Surviving a Decade or More After Coronary Revascularization in a Middle Eastern Population","phase":"","overall_status":"COMPLETED","enrollment_count":1000,"lead_sponsor_name":"Jordan Collaborating Cardiology Group","has_results":false},{"nct_id":"NCT07496567","title":"A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)","phase":"PHASE2, PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":960,"lead_sponsor_name":"EyeBiotech Ltd.","has_results":false},{"nct_id":"NCT07440225","title":"A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":960,"lead_sponsor_name":"EyeBiotech Ltd.","has_results":false},{"nct_id":"NCT01881555","title":"Functional Testing Underlying Coronary Revascularisation","phase":"NA","overall_status":"COMPLETED","enrollment_count":941,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT06546228","title":"Long Term Predictors of Acute Myocardial Infarction in Patients With Coronary Revascularization","phase":"","overall_status":"COMPLETED","enrollment_count":652,"lead_sponsor_name":"Azienda Ospedaliera Universitaria Policlinico \"G. Martino\"","has_results":false},{"nct_id":"NCT01948830","title":"Randomized Study for Efficacy and Safety of Ranibizumab 0.5mg in Treat-extend and Monthly Regimens in Patients With nAMD","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":650,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT05130385","title":"High Resolution Optical Coherence Tomography","phase":"","overall_status":"UNKNOWN","enrollment_count":550,"lead_sponsor_name":"Insel Gruppe AG, University Hospital Bern","has_results":false},{"nct_id":"NCT03211741","title":"Longterm Efficiency and Safety of Intravitreal Injections With Bevacizumab in Patients With Neovascularisation or Macular Edema","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"University Hospital, Ghent","has_results":false},{"nct_id":"NCT01922102","title":"Efficacy and Safety of Ranibizumab 0.5 vs Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":457,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT05614180","title":"Chronic Total Occlusive Lesions CMR Study","phase":"","overall_status":"UNKNOWN","enrollment_count":400,"lead_sponsor_name":"Lin Zhao","has_results":false},{"nct_id":"NCT06686121","title":"Improving Mobility After Revascularization in Peripheral Artery Disease","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":386,"lead_sponsor_name":"Northwestern University","has_results":false},{"nct_id":"NCT02260687","title":"Special Drug Use Investigation of EYLEA for Myopic Choroidal Neovascularization","phase":"","overall_status":"COMPLETED","enrollment_count":353,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT01972789","title":"Comparison of Treatment Regimens Using Ranibizumab: Intensive (Resolution of Intra- and Sub-retinal Fluid) vs Relaxed (Resolution of Intra-retinal Fluid and/or Sub-retinal Fluid >200µm at the Foveal Centre)","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":349,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT05619068","title":"The Evolution and Prognosis of Moyamoya Disease","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Chinese PLA General Hospital","has_results":false},{"nct_id":"NCT06176352","title":"A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":280,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT02484690","title":"A Proof-of-Concept Study of Faricimab (RO6867461) in Participants With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":273,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT01908816","title":"An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":270,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT05835167","title":"Complete Revascularization Via Inferior Part-sternotomy","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":260,"lead_sponsor_name":"China National Center for Cardiovascular Diseases","has_results":false},{"nct_id":"NCT04439708","title":"Biomarkers and Choroidal Neovascularization","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":250,"lead_sponsor_name":"Institut National de la Santé Et de la Recherche Médicale, France","has_results":false},{"nct_id":"NCT05494775","title":"Effect of Corona Virus on Intravitreal Injections","phase":"NA","overall_status":"UNKNOWN","enrollment_count":250,"lead_sponsor_name":"Benha University","has_results":false},{"nct_id":"NCT07314138","title":"Multivessel Minimally Invasive Coronary Bypass Grafting as HYBRID Revascularization Versus Conventional Off-pump Coronary Artery Bypass Grafting","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":250,"lead_sponsor_name":"Catharina Ziekenhuis Eindhoven","has_results":false},{"nct_id":"NCT00511706","title":"Safety and Efficacy of a New Treatment as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) Treatment in Patients With Age-Related Macular Degeneration (AMD)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":243,"lead_sponsor_name":"Allergan","has_results":true},{"nct_id":"NCT02034006","title":"A Study of the Criteria Establishing the Need for Re-treatment With Ranibizumab Upon Relapse in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":200,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT05803759","title":"The Effects of Allicor on Patients After Coronary Arteria Revascularization Treatment","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"Institute for Atherosclerosis Research, Russia","has_results":false},{"nct_id":"NCT04455399","title":"Time Efficiency Comparison of Two IntraVitreal Injection Techniques","phase":"NA","overall_status":"COMPLETED","enrollment_count":200,"lead_sponsor_name":"Peregrine Eye and Laser Institute","has_results":false},{"nct_id":"NCT04683133","title":"The FAST OCT Study","phase":"NA","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"Erasmus Medical Center","has_results":false},{"nct_id":"NCT07002372","title":"Effect of Video Viewing on Intravitreal Injection Experience","phase":"NA","overall_status":"RECRUITING","enrollment_count":182,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT06924593","title":"Study on the Trans-Carotid Artery Occlusion Shunt System","phase":"NA","overall_status":"RECRUITING","enrollment_count":162,"lead_sponsor_name":"Shenzhen Wecan Medical Technology Co.,Ltd","has_results":false},{"nct_id":"NCT06629701","title":"A Prospective Randomized Trial of External Vein Graft Support in Surgical Myocardial Revascularization","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":150,"lead_sponsor_name":"University Hospital Pilsen","has_results":false},{"nct_id":"NCT05662943","title":"Outcomes of Tolerating Subretinal Fluid in Type 1 MNV and PCV","phase":"","overall_status":"COMPLETED","enrollment_count":135,"lead_sponsor_name":"Kim's Eye Hospital","has_results":false},{"nct_id":"NCT02317237","title":"\"GOLIATH\" - General Or Local Anaestesia in Intra Arterial THerapy","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":128,"lead_sponsor_name":"University of Aarhus","has_results":false},{"nct_id":"NCT07212842","title":"Methylene Blue-Enhanced Ultrafiltration Improves Outcomes After Cardiopulmonary Bypass","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":124,"lead_sponsor_name":"University of Sao Paulo","has_results":false},{"nct_id":"NCT05315349","title":"Retinal Microvascular Network and Coronary Revascularization Surgery at the Dijon University Hospital","phase":"NA","overall_status":"COMPLETED","enrollment_count":120,"lead_sponsor_name":"Centre Hospitalier Universitaire Dijon","has_results":false},{"nct_id":"NCT03838679","title":"Imaging of the Angiofibrotic Switch in Neovascular AMD","phase":"","overall_status":"UNKNOWN","enrollment_count":120,"lead_sponsor_name":"Medical University of Vienna","has_results":false},{"nct_id":"NCT05306119","title":"Developing a Method of Rehabilitation for Patients After Myocardial Revascularization","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":120,"lead_sponsor_name":"Gomel State Medical University","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}